Connect Biopharma’s (CNTB) Buy Rating Reiterated at HC Wainwright

Posted by Stanley Muller on Oct 31st, 2026

HC Wainwright reaffirmed their buy rating on shares of Connect Biopharma (NASDAQ:CNTB – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports.

CNTB has been the subject of several other reports. Weiss Ratings cut shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Canaccord Genuity Group reduced their target price on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, September 16th. BTIG Research decreased their price target on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Oppenheimer decreased their price target on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, September 22nd. Finally, Leerink Partners began coverage on Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target for the company. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Connect Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $5.88.

Check Out Our Latest Stock Report on CNTB

Connect Biopharma Stock Down 4.0%

Shares of CNTB opened at $0.80 on Wednesday. The firm has a market capitalization of $50.52 million, a P/E ratio of -0.67 and a beta of -0.16. Connect Biopharma has a 12-month low of $0.73 and a 12-month high of $3.82. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $1.36 and a 200-day moving average price of $2.19.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million during the quarter, compared to the consensus estimate of $0.74 million. Equities research analysts expect that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Trading of Connect Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new position in Connect Biopharma during the 1st quarter worth about $41,000. ADAR1 Capital Management LLC purchased a new position in Connect Biopharma during the 1st quarter valued at about $1,945,000. Knott David M Jr raised its holdings in shares of Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of Connect Biopharma in the 1st quarter valued at about $135,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases driven by T-cell activity. The company’s research programs target conditions in immunology, including inflammatory bowel disease, atopic dermatitis and other immune-mediated disorders.

Its pipeline has included rademikibart, formerly known as CBP-201, an investigational monoclonal antibody designed to block the interleukin-4 receptor alpha pathway, and ropsacitinib, formerly known as CBP-307, an investigational oral TYK2 inhibitor.